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Background/aim: The aim of the study is to assess expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and
CTNNB1 genes in tumors and peripheral bloods of colorectal cancer patients in stages I–IV.
Materials and methods: The mRNA levels of the genes were determined in tumor tissues and peripheral blood samples of 45 colorectal
cancer patients and colon tissues and peripheral blood samples of 5 healthy individuals. Real-time polymerase chain reaction method
was used for the analysis.
Results: The mRNA level of the CPEB4 gene was significantly downregulated in colorectal tumor tissues and was upregulated in the
peripheral blood of colorectal cancer patients relative to the controls (P < 0.05). APC mRNA level was significantly downregulated
in tissues and upregulated in the peripheral blood (P < 0.05). TRIP13 mRNA level was upregulated in peripheral blood and also
significantly upregulated in colorectal tumor tissues (P < 0.05). EIF2S3 mRNA level was upregulated in tissues and also significantly
upregulated in peripheral blood (P < 0.05). PIK3CA mRNA level was downregulated in tissues and upregulated in peripheral blood.
EIF4A1 mRNA level was downregulated in tissues and significantly upregulated in peripheral blood (P < 0.05). CTNNB1 mRNA level
was downregulated in tissues and upregulated in peripheral blood. IFNg mRNA level was upregulated in both colorectal cancer tumor
tissues and peripheral blood.
Conclusion: TRIP13 and CPEB4 mRNA up regulation in the peripheral blood of patients with colorectal cancer may be a potential
target for early stage diagnosis. In addition to this evaluation, although there is not much study on EIF2S3 and EIF4A1 mRNA changes
in cases with colorectal cancer, upregulation in peripheral blood draws attention in our study. These data will shed light on the new
comprehensive studies.
Key words: Biomarker, colorectal tumor, different stage, gene expression

1. Introduction
Cancers originating from the colon or rectum are
called colorectal cancer. Colorectal cancer is the third
most common cancer type in the world and the fourth
most common cause of cancer-related deaths [1]. Early
diagnosis is associated with improving prognosis and
associated with the identification of genetic biomarkers
and the development of available diagnostic tools [2]. The
application of gene expression profiling on carcinogenesis
studies purposes to identify specific alterations on gene
expression according to tumour development and to
diagnose and classify tumours on the basis of molecular
features [3]. Several studies have been conducted to

investigate the difference in gene expression levels
between tumor and normal colorectal tissues and have
reported significant differences in gene expression profiles
between adenoma and normal mucosa. Among these
studies, certain groups of genes have been reported to be
of differently expressed and consequently help distinguish
cancerous tissues from normal ones [4–10]. Ortiz-Zapater
et al. [11] reported that CPEB4-associated mRNAs are
significantly enriched in a number of cellular functions that
are relevant to tumorigenesis. The adenomatous polyposis
coli (APC) gene is a key tumor suppressor gene. Mutations
in APC gene are the basis of hereditary predisposition to
colorectal cancer in familial adenomatous polyposis coli
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(FAP) and also the primary reason for the formation of
sporadic colorectal tumors. Mutant APC may also impair
cytoskeleton adhesion and stability, which play a role
in cancer progression. A better understanding of both
genetics and biological function of APC may help develop
preventive or therapeutic regimes that aim to reduce
the burden of colorectal cancer over time [12]. Somatic
mutations in the CTNNB1 gene have been identified
in several types of cancer including include colorectal,
liver, thyroid, ovarian, endometrial and skin cancers and
medulloblastoma. TRIP13 has been found to play a key
role in meiotic recombination, spindle checkpoint and
chromosome synapses [13]. Studies have shown that
TRIP13 is overexpressed in multiple neoplasms [14–16].
Sheng et al. [17] suggested that TRIP13 can support
colorectal cancer cell proliferation, migration and invasion
in vitro, and reported low survival times for colorectal
cancer patients. IFNg is a critical proinflammatory
cytokine for natural and adaptive immunity against viral
and intracellular bacterial infections and tumor control.
IFNg is also important for the activation of macrophages in
response to intracellular bacteria and viruses. Decreased
IFNg induction or signal has also been demonstrated to
be associated with increased sensitivity to intracellular
bacteria, some viruses and tumor onset [18]. PIK3CA is a
proto-oncogene encoding phosphatidylinositol-3-kinases
(PI3K) located in the EGFR tyrosine-kinase domain and
leads to the activation of AKT’s phosphorylation and the
AKT-mTOR signal path. The phosphoinositol-3-kinase
(PI3K) pathway has been discovered as an enzymatic
activity associated with a viral oncoprotein in human
cancers. This pathway has attracted a lot of attention
in human cancer studies because it is important for cell
cycle, proliferation, growth, survival, protein synthesis,
and glucose metabolism [19]. The EIF2S3 gene encodes
the core subunit of eukaryotic translation initiation
factor-2 (eIF2), a heterotrimeric GTP binding protein
involved in the incorporation of methionyl-tRNA (i) into
the 40S ribosomal subunit. EIF2 complex is required for
protein synthesis [20]. EIF4A is a member of the DEAD
box protein family and functions as an ATP-bound RNA
helicase to catalyze the dissolution of the mRNA secondary
structure at 5’UTR [21].
Among all the genes reported in the literature with
their potential cause in tumor development, CPEB4, APC,
TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1
have particularly been identified to be a set of potential
candidates for tumor development. Therefore, in this study,
they have been experimentally studied by considering
their expression level in 45 colorectal cancer patients who
were at different stages of their disease. It is discovered
that these genes exist in tumors and peripheral bloods, but
with varying expression levels, which appears to suggest

662

that they may help distinguish patients and their disease
stages, consequently understand molecular mechanism of
the disease.
2. Materials and methods
2.1. Sample collection and clinicopathological
information
Fifty patients who underwent surgical resection in the
Department of General Surgery, Afyonkarahisar Health
Sciences University between April 2018 and December
2019 were chosen for the study. Tissues and blood samples
were obtained from the patients with histopathologically
confirmed colorectal carcinoma (26 male and 19 female
patients). Of the fifty patients, five are noncolorectal
cancer subjects and selected as controls. The stage of cancer
was estimated on the basis of the TNM and American Joint
Committee on Cancer classifications.
2.2. RNA extraction, real-time PCR and RT-PCR analyses
The fresh samples were transported in liquid nitrogen and
stored in –80 °C until RNA extraction. About 5 mL peripheral blood samples were stored in EDTA-coated vacutainers and RNA extractions were immediately performed.
RNA extractions of tissues and peripheral blood samples
were performed by using EZ-RNA Total RNA extraction
kit (BI, Israel, Cat. No: 20-400-100) according to the manufacturer’s protocol. Then, RNA amount and RNA purity
were quantified for each RNA sample by Nanodrop ND1000 spectrophotometer V3.7. RNA samples were stored
at –80 °C until use. All the RNA samples were reverse
transcribed into cDNA from 1 µg of total RNA (iScript
Reverse Transcription Supermix, Bio-Rad Laboratories,
Hercules, CA, USA, Cat. No: 170884) under the following conditions: One cycle at 25 °C for 5 min, 46 °C for 20
min and 95 °C for 1 min. Real-time PCR was performed
after reverse transcription. mRNA expression analysis of
all the genes was performed by using the Rotor Gene-Q
(Qiagen, Hilden, Germany). cDNAs that belong to the
cases were added to iTaq Universal SYBR Green Supermix
(Biorad Laboratories, Kat. No: 1725122) according to the
manufacturer’s protocol. Oligonucleotide primers were
designed by Oligomere Biotechnology (Ankara, Turkey)
based on following primer sequences:
CPEB4-F: 5’-CATATTCAGCTCCAGAAGTATGCTC-3’
CPEB4-R: 5’-AGTGCATGTCGAATGTCCTG-3’
APC-F: 5’-AAAATGTCCCTCCGTTCTTATGG-3’
APC-R: 5’-CTGAAGTTGAGCGTAATACCAGT-3’
TRIP13-F: 5’-ACTGTTGCACTTCACATTTTCCA-3’
TRIP13-R: 5’-TCGAGGAGATGGGATTTGACT-3’
EIF2S3-F: 5’-GTATCACTTTTTGCGGAGCAT-3’
EIF2S3-R: 5’-GGGGTCAATTTTTGTTCCAA-3’
EIF4A1 F: 5’-AAGGCGTCATCGAGAGTAACT-3’
EIF4A1 R: 5’-ATGTGGCCGTTTTCCCAGTC-3’
IFNg-F: 5’-TCAGCTCTGCATCGTTTTGG-3’
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IFNg-R: 5’-GTTCCATTATCCGCTACATCTGAA-3’
PIK3CA-F: 5’-CCTGATCTTCCTCGTGCTGCTC-3’
PIK3CA-R: 5’-ATGCCAATGGACAGTGTTCCTCTT-3’
CTNNB1-F: 5’-CTTGCTCAGGACAAGGAAGC-3’
CTNNB1-R: 5’-CATATGTCGCCACACCTTCA-3’
GAPDH-F: 5’-CATTGCCCTCAACGACCACTTT-3’
GAPDH-R: 5’-GGTGGTCCAGGGGTCTTACTCC-3’.
We used the following RT-PCR protocol for CPEB4, APC,
TRIP13, EIF2S3, EIF4A1, CTNNB1: 95 °C for 30 s initial
denaturation followed by 40 cycles of 95 °C for 5 s and 60
°C for 30 s, and for IFNg, PIK3CA: 95 °C for 30 s initial
denaturation followed by 40 cycles of 95 °C for 5 s and
63 °C for 30 s. Melting curve analysis was performed for
confirmation of single product amplification at the end of
the PCR. 65–95 °C, 0.5 °C increments at 5 s/step. Each run
has been performed triplicate.
2.3. Statistical analysis
All the data analyses were performed using REST 2009
V2.0.13 and SPSS v.19 software which use pairwise fixed
reallocation randomization test [22] where P < 0.05 is
deemed to represent a statistically significant result.
REST 2009 Software is a standalone tool for analysis of
gene expression data from quantitative, real-time PCR
experiments. The analysis or quantitation of relative gene
expression uses expression of reference genes to normalize
expression levels of genes of interest in different samples.
3. Results
The study included 45 patients (average age: 66.6 ± 12.66)
with pathologically proven colorectal carcinoma and 5
control patients (average age: 62.5 ± 11.08). Cancer tissues
and blood samples were collected for each of the cases. In

colorectal cancer, tumor localization was in the rectum for
17 patients and in the colon for 26 patients. Of 45 patients,
the number of patients at stages I, II, III and IV are 8, 17,
15 and 5, respectively.
3.1. Gene expression analysis
The mRNA levels of CPEB4, APC, TRIP13, EIF2S3,
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in
colorectal cancer tissue specimens, colorectal cancer blood
samples, normal colon tissues and blood samples were
analysed.
3.1.1. mRNA analysis of CPEB4, APC, TRIP13, EIF2S3,
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in
normal and cancer tissues
Changes in mRNA levels of related genes expressed in
tumor tissues of colorectal cancer (CRC) cases were
determined according to the tissues of the control
group. While the mRNA levels of CPEB4 and APC genes
decreased significantly compared to the control group
(0.512 and 0.594 fold regulation value, respectively) (P <
0.05), the mRNA level of the TRIP13 gene significantly
increased (2.139) (P < 0.05). The mRNA levels of EIF2S3
and IFNg genes increased compared to the control group,
while the mRNA level of EIF4A1, PIK3CA and CTNNB1
genes decreased (Figure 1).
3.1.2 mRNA analysis of CPEB4, APC, TRIP13, EIF2S3,
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in
normal and cancer peripheral blood samples
Changes in mRNA levels of related genes expressed in
peripheral blood samples of colorectal cancer cases were
determined according to the peripheral blood samples of
the control group. The mRNA levels of the CPEB4, APC,
EIF2S3 and EIF4A1 genes were significantly increased

Figure 1. The results of real-time PCR analysis. The up/down regulation of genes in tissues of colorectal cancer (CRC) patient were
given as fold regulation levels. * represents the significance of P< 0.05 compared to control. GAPDH is reference gene for normalization.

663

SÖYLEMEZ et al. / Turk J Med Sci
compared to the control group (2.467; 2.066; 1.852; 1.522
fold regulation value; respectively) (P < 0.05). The mRNA
levels of TRIP13, IFNg, PIK3CA and CTNNB1 genes also
increased (Figure 2).
3.1.3. mRNA analysis of CPEB4, APC, TRIP13, EIF2S3,
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in
tumor tissues of stages I–IV colorectal cancer patients
Changes in mRNA levels of related genes expressed in
tumor tissues of stages I–IV colorectal cancer cases were
determined according to the tissues of the control group.
The findings for each stage are as follows:
Stage I: The mRNA levels of the CPEB4 and CTNNB1
genes decreased significantly compared to the control
group [0.250 (P < 0.001); 0.204 (P < 0.05) fold regulation
value; respectively]. While TRIP13 and EIF2S3 mRNA
levels increased compared to the control group, mRNA
levels of APC, EIF4A1, IFNg and PIK3CA genes decreased
(Figure 3).
Stage II: While mRNA levels of CPEB4, APC, PIK3CA and
CTNNB1 genes decreased compared to the control group,
TRIP13, EIF2S3, EIF4A1 and IFNg mRNA levels increased
(Figure 4).
Stage III: mRNA levels of CPEB4, APC, EIF4A1, PIK3CA
and CTNNB1 genes decreased compared to the control
group, whereas TRIP13, EIF2S3 and IFNg mRNA levels
increased (Figure 5).
Stage IV: The mRNA level of the APC gene significantly
decreased compared to the control group [0.333 fold
regulation value, (P < 0.05)]. In addition, CPEB4, EIF2S3,
EIF4A1 PIK3CA and CTNNB1 mRNA levels decreased
compared to the control group, while TRIP13 and IFNg
mRNA levels increased (Figure 6).

3.1.4. mRNA analysis of CPEB4, APC, TRIP13, EIF2S3,
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed
in peripheral blood samples of stages I–IV colorectal
cancer patients
Changes in mRNA levels of related genes expressed in
peripheral blood samples of stages I–IV colorectal cancer
cases were determined according to the peripheral blood
samples of the control group. The findings for each stage
are as follows:
Stage I: The mRNA levels of CPEB4, TRIP13, EIF2S3,
CTNNB1, EIF4A1 genes significantly increased compared
to the control group [2.803; 3.553; 2.507; 3.548 (P < 0.05);
2.441; (P < 0.001) fold regulation value; respectively]. The
mRNA levels of the APC, IFNg and PIK3CA genes also
increased compared to the control group (Figure 7).
Stage II: The mRNA levels of CPEB4 and TRIP13 genes
significantly increased compared to the control group
[2.788; 1.943 fold regulation value (P < 0.05)]. The mRNA
levels of the APC, EIF2S3, EIF4A1 and CTNNB1 genes also
increased compared to the control group, while the mRNA
levels of the IFNg and PIK3CA genes decreased (Figure 8).
Stage III: The mRNA levels of APC, TRIP13, EIF2S3 and
EIF4A1 genes significantly increased compared to the
control group [2.47; 2.696; 2.32; 1.838 fold regulation
value (P < 0.05)]. The mRNA levels of CPEB4, IFNg,
PIK3CA and CTNNB1 genes also increased compared to
the control group (Figure 9).
Stage IV: While mRNA levels of CPEB4, APC and
PIK3CA genes increased compared to the control group,
TRIP13, EIF2S3, EIF4A1, IFNg and CTNNB1 mRNA levels
decreased (Figure 10).

Figure 2. The results of real-time PCR analysis. The up regulation of genes in peripheral blood of colorectal cancer patient were given as
fold regulation levels. * represents the significance of P < 0.05 compared to control. GAPDH is reference gene for normalization.
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Figure 3. The results of real-time PCR analysis. The up/down regulation of genes in tissues
of stage I colorectal cancer patients were given as fold regulation levels. * represents the
significance of P < 0.05 compared to control. GAPDH is reference gene for normalization.

Figure 4. The results of real-time PCR analysis. The up/down regulation of genes
in tissues of stage II colorectal cancer patients were given as fold regulation levels.
GAPDH is reference gene for normalization.

4. Discussion
In colorectal cancer, a comprehensive list of biomarkers with
quite different expression patterns can be used as molecular
markers to complement existing histopathological factors
in patients’ follow-up and treatment strategies. Although
screening tests are becoming increasingly important, colon
cancer cases are often diagnosed at an advanced stage of the
tumor, where the chances of survival are greatly reduced. It
is well known that various gene expression differences can
be detected during colon cancer development. On the basis
of all genome expression studies, it is intended to identify

clinically useful biomarkers and then be developed and
used as part of routine diagnosis in tumor classification
[23].
4.1. Relationship between colorectal cancer and CPEB4
gene expression
Abnormal expression of CPEB4 is associated with certain
types of cancer, suggesting that CPEB4 can play critical
roles in the control of cancer proliferation and metastasis
[24]. In particular, it is suggested that CPEB4 plays an
important role in the migration and invasion of cancer
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Figure 5. The results of real-time PCR analysis. The up/down regulation of genes in tissues of
stage III colorectal cancer patients were given as fold regulation levels. GAPDH is reference gene
for normalization.

Figure 6. The results of real-time PCR analysis. The up/down regulation of genes in tissues
of stage IV colorectal cancer patients were given as fold regulation levels. * represents the
significance of P < 0.05 compared to control. GAPDH is reference gene for normalization.

cells in certain types of cancer, and can be used as a target
for cancer treatment [11, 24–26]. In addition, it is of
great interest to identify cancer-associated RNA-binding
proteins, to understand colorectal cancer biology, and
to potentially set new goals with cancer treatment and
prognostic biomarkers [27]. It has been reported that
colorectal cancer tissues express high levels of CPEB4 and
that high mRNA level is associated with advanced tumor
stage, lymph node metastasis, distant metastasis and poor
prognosis in patients with colorectal cancer [28].
In our study, CPEB4 mRNA level was significantly
decreased in all colorectal tumor tissues. However, similar
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to our study, Xu and Liu [24] reported that CPEB4’s mRNA
level decreased compared to control in prostate cancer
and adjacent tissues. Considering the studies, there are
different results related to CPEB4 in different types of
tumor tissues. CPEB4 is thought to affect tumor growth,
invasion and vascularization by applying preoncogenic
effects, since the high level of expression of CPEB4 has
been defined in a wide variety of malignancies [11]. In
addition, CPEB4 gene expression has been reported to be
relatively low in NSCLC samples compared to adjacent
non-cancerous tissues [29]. In another study, CPEB4 gene
expression was reported to increase in pancreatic ductal

SÖYLEMEZ et al. / Turk J Med Sci

Figure 7. The results of real-time PCR analysis. The up regulation of genes in peripheral blood of
stage I colorectal cancer patients were given as fold regulation levels. * represents the significance of
P<0.05, ** represents the significance of P< 0.001 compared to control. GAPDH is reference gene for
normalization.

Figure 8. The results of real-time PCR analysis. The up/down regulation of genes in
peripheral blood of stage II colorectal cancer patients were given as fold regulation levels.
* represents the significance of P < 0.05. GAPDH is reference gene for normalization.

carcinoma [11] but decreased in hepatocellular carcinoma
[30]. When liver samples taken from 125 hepatocellular
carcinoma patients were compared with 49 controls, it
was reported that the protein level of CPEB4 increased
in early stage hepatocellular carcinoma and decreased in
late stage hepatocellular carcinoma [31]. These changes
in the expression of CPEB4 during the progression of
hepatocellular carcinoma suggest that it plays a complex
role in tumorigenesis. It has been suggested that CPEB4
gene expression is directly proportional to the pathological
degree of glioma, increased CPEB4 gene expression in

primary tumors in predicting poor outcomes in patients,
and suppressed CPEB4 gene expression inhibits tumor
cell proliferation and is a potential therapeutic target for
glioblastoma [32]. However, Hu et al. [33] reported that
CPEB4 gene expression increases significantly in glioma
and this increase is directly proportional to the advanced
cancer stage. It has been reported that for patients with
glioma, CPEB4 may be a highly sensitive prognostic
indicator. It is thought that CPEB4 is over-expressed in a
wide variety of tumors, including colorectal cancer, skin
cancer and kidney cancer, and high expression of CPEB4
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Figure 9. The results of real-time PCR analysis. The up regulation of genes in peripheral blood of
stage III colorectal cancer patients were given as fold regulation levels. * represents the significance
of P < 0.05 compared to control. GAPDH is reference gene for normalization.

Figure 10. The results of real-time PCR analysis. The up/down regulation of genes in peripheral
blood of stage IV colorectal cancer patients were given as fold regulation levels. GAPDH is reference
gene for normalization.

may also be effective in tumor development. It has been
suggested that CPEB4 is important in tumor invasion
and metastasis processes, and high expression level is an
indicator for poor outcome in colorectal cancer patients
[34]. In addition, Xu and Liu [24] reported a similar
result in invasive and metastatic cancers. In addition,
CPEB4 has also been reported to be highly expressed
in the peripheral blood of cases with colorectal cancer
[35]. Similar to this study, in our study, CPEB4 mRNA
level increased significantly in the peripheral blood of
patients with colorectal cancer. When compared in terms
of stages, this increase was important in stages I and II.
This suggests that CPEB4 gene expression in peripheral
blood from the early stages of colorectal cancer may be an
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indicator for colorectal cancer. It has been suggested that
such gene expression changes may be related to different
pathways regulated by CPEB4 in different types of cells. It
has been suggested that such gene expression changes may
be related to different pathways regulated by CPEB4 in
different types of cells [29]. In our study, while the mRNA
level of the CPEB4 gene was significantly decreased in all
colorectal tumor tissues of the cases, it was observed that
it is increased significantly in peripheral blood samples.
When evaluated comparatively in terms of stages, the
increase in the mRNA level of CPEB4 gene was found to
be statistically significant in the peripheral blood samples
of cases in colorectal cancer stages I and II. This suggests
that the increase in CPEB4 mRNA level in peripheral

SÖYLEMEZ et al. / Turk J Med Sci
blood since the early stages of colorectal cancer may be a
potential biomarker for colorectal cancer.
4.2. Relationship between colorectal cancer and APC
gene expression
Although there are many studies related to APC mutations
in literature searches, there is not much study on gene
expression. Birnbaum et al. [36] investigated the role of
the APC gene in the 183 colon adenocarcinoma series, by
combined analysis of gene expression, mutation, allelic
loss, and promoter methylation and metastasis formation.
While spot mutations were detected in 73% of cases and
allelic losses in 39% of cases; 59% of tumors showed
bialelic inactivation. No relationship was found between
the number and type of APC gene expression changes
and metastatic transformation. The results show that
determining the APC status cannot help for the prediction
of metastasis and cannot be used to classify stage II colon
cancers. In our study, the mRNA level of the APC gene
was significantly decreased in all colorectal tumor tissues,
while the peripheral blood of the same cases increased
significantly. When compared in stages, this increase was
also important in stage III. When evaluated in terms of
stages, while the increase in the mRNA level of the APC
gene in the peripheral blood samples of the patients
in colorectal cancer stage III, the decrease in stage IV
tumor tissues was significant. These results indicate that
determining APC mRNA levels cannot assist in predicting
colorectal cancer and cannot be used to classify the stages
of colon cancer.
In the study of Güler [37], 8 of 20 patients with
colorectal carcinoma reported that there was a mutation
in the APC gene, whereas in the rest, the expression
of the APC gene was significantly different compared
to the control group. It has been suggested that APC is
overexpressed in NIH3T3 fibroblast cells to block cell
cycle progression from serum-induced G0/G1 to S phase
[38]. Consistent with these data, it has been suggested
that APC is overexpressed to prevent transition to the
G1 phase in colorectal cancer cell lines. This function is
partially associated with the regulation of the β-catenin/
Tcf mediated transcription of S-phase regulators such as
cyclic D1 and c-myc [39]. It has been suggested that APC
can also affect proliferation independently of β-catenin.
Thus, deactivation of the mutant APC at the G1/S control
point can contribute to aberrant cell proliferation. Copy
number changes, regulatory changes, deletions, severe
mutations and other potential causes are difficult to
distinguish through APC mRNA expression data. In other
words, more studies are needed to demonstrate causality
correlation with respect to APC mRNA changes. The
results obtained as a result of mRNA analyses are not
sufficient for any necessary information such as mutation
status and other clinicopathological features. Further

study is therefore required for developing preventive or
therapeutic strategies that may be developed over time,
especially aimed at reducing the colorectal cancer burden.
4.3. Relationship between colorectal cancer and CTNNB1
gene expression
The CTNNB1 gene encodes β-catenin. β-catenin plays an
important role in the adhesion of cells and communication
between cells. Somatic mutations in the CTNNB1 gene
have been identified in many types of cancer. If β-catenin
does not phosphorylate and therefore does not break down,
it accumulates in the cellular cytoplasm and nucleus. The
accumulation of the β-catenin may result from the Wnt
signal [40] by inactivation of the APC or direct mutation of
the β-catenin itself [41]. Mutations in the APC or CTNNB1
genes inhibit GSK3β-mediated phosphorylation followed
by β-catenin degradation [42] and result in activation of
the catenin transcription [43]. This critical role of Wnt
in intestinal homeostasis is the basis for understanding
why Wnt path deregulation contributes to colorectal
carcinogenesis. Of the known Wnt signal cascades, Wnt/
β-catenin (canonical pathway) mutates in about 90% of
colorectal cancers. These mutations are mainly found in
the genes of APC and β-catenin and both lead to pathway
activation, but other path components may also harbor
mutations [44]. Signal activation of Wnt-β-catenin leads to
accumulation of catenin, which can be detected in >80% of
colorectal cancer tumors in the nucleus [45]. In addition,
high nuclear catenin levels have been correlated with poor
prognosis in colorectal cancer patients [46]. In our study,
CTNNB1 mRNA level decreased in tumor tissues compared
to the control group, while it increased in peripheral blood
samples. In particular, different mRNA levels were found
in stage I colorectal cancer tissues and peripheral blood
samples. These different results we obtained support the
view that the changes in CTNNB1 mRNA level may not be
useful in colorectal cancer diagnosis.
4.4. Relationship between colorectal cancer and TRIP13
gene expression
TRIP13 has been found to play a key role in meiotic
recombination, spindle checkpoint and chromosome
synapses [13]. Studies have shown that TRIP13 is
overexpressed in multiple neoplasms [14–16]. TRIP13 has
been shown to be a localized protein in the kinetochore
that allows cell division to progress correctly. A number
of kinetochore-localized proteins are highly synthesized
in various cancers, and their expression is associated with
genomic imbalance or malignant transformation of cancer
cells [47]. Although it plays an important role in meiotic
regulation, excessive expression or amplification of TRIP13
has been found in more than one human cancer [48,49].
In our study, TRIP13 mRNA level increased significantly
in both colorectal tumor tissues and peripheral blood
compared to the control group. Similarly, Kurita et al.
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[50] analyzed the mRNA level of TRIP13 between normal
and tumor tissues. They suggest that TRIP13 is involved
in colorectal cancer cell proliferation and invasion,
and may be a potential indicator for colorectal cancer
treatment. Sheng et al. [17] analyzed multiple colorectal
cancer datasets available from Oncomine to determine
the expression profile of TRC13 in colorectal cancer, and
found that gene expression of TRIP13 increased in tumor
tissue compared to that of normal tissue. To confirm the
results, 41 pairs of colorectal cancers and TCGA (Cancer
Genome Atlas) examined the mRNA level of TRIP13 in the
corresponding normal tissues, and reported that TRIP13
was expressed in tumor tissue at a high rate (P < 0.001).
In our study, the increase in TRIP13 mRNA level is
important especially in peripheral blood stages I, II, and
III. In the development of colorectal cancer, high mRNA
level of TRIP13 can be observed from the early stage.
Sheng et al. [17] reported that high TRIP13 expression
was significantly associated with advanced pTNM stage.
High TRIP13 expression has been shown to reveal poor
course in other carcinomas such as renal renal clear cell
carcinoma, renal papillary cell carcinoma, brain low grade
glioma, liver hepatocellular carcinoma in total survival
(OS: overall survival) analysis. Therefore, abnormal
expression of TRIP13 is a common occurrence in cancer
cells. It shows a potential oncogenic role of TRIP13
in cancer development [51]. Considering the findings
mentioned above, TRIP13 appears to contribute to tumor
formation and tumor progression in various human
cancers. In human mycosis fungoides tumor, TRIP13 gene
expression increased compared to control biopsies [52].
What is important here is that TRIP13 gene expression
and activity are required for accurate chromosome
segregation. It is strongly suggested that TRIP13 is an
oncogene when it is possible to monitor the suitability of
chromosome segregation with various pathways and its
effects on cell physiology [50]. Our results support this view.
In our study, TRIP13 mRNA levels increased significantly
in both colorectal tumor tissues and peripheral blood
samples compared to controls. This increase in peripheral
blood samples, especially in cases of colorectal cancer
stages I, II, and III, seems to be significant. An increase
in the level of mRNA of TRIP13 can be observed in the
development of colorectal cancer from an early stage.
TRIP13 strongly suggests that overexpression may be a
common phenotype in colorectal cancer and a potential
finding/biomarker for early stage colorectal cancer
diagnosis.
4.5. Relationship between colorectal cancer and IFNg
gene expression
Interferons can also have a bidirectional effect on cancer
cell behavior, such as promoting proliferation or growth
inhibition. Indeed, contradictory results have been report-
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ed regarding the interferons function as tumor promoters
or tumor suppressors in melanoma and colorectal cancer.
The differences may arise from different experimental environments, such as the effect of the microenvironment,
the amount and quality of the immune infiltrate, and the
mutation status of cancer cells. Therefore, there is a need
to better understand the biology of interferons in cancer
and analyze the data depending on the conditions [53]. In
our study, IFNg mRNA levels increased in tumor tissues
and peripheral blood samples of colorectal cancer group
compared to the control group. However, this increase was
not statistically significant. When the data were evaluated
in terms of stages, different changes were observed in the
mRNA levels according to the data of the control group
individuals. Studies to clarify the effect of IFNg on the
colorectal cancer process are very new and future studies
are needed.
4.6. Relationship between colorectal cancer and PIK3CA
gene expression
PIK3CA
is
a
proto-oncogene
encoding
phosphatidylinositol-3-kinases (PI3K) located in the
EGFR tyrosine-kinase domain. It leads to phosphorylation
of AKT (protein kinase B) and activation of the AKTmTOR signaling pathway. The phosphoinositol-3-kinase
(PI3K) pathway has been discovered as an enzymatic
activity associated with a viral oncoprotein in human
cancers. This pathway has attracted a lot of attention
in human cancer studies because it is important for cell
cycle, proliferation, growth, survival, protein synthesis
and glucose metabolism [19]. In our study, it was found
that PIK3CA mRNA levels decreased in colorectal
tumor tissues compared to control, while it increased in
peripheral blood compared to the control group. However,
these changes are not statistically significant. PIK3CA, the
catalytic subunit of PI3K, undergoes mutation in many
different tumors, including colorectal cancer [54,55].
PIK3CA mutations have been reported in about 80% of
mutations in 10%–20% of colorectal cancers, exon 9 and
exon 20 at two hot spots [55]. It has been suggested that
PIK3CA mutations may be a long-sought biomarker for
successful adjuvant therapy with aspirin in colorectal
cancer patients. Therefore, PIK3CA mutations appear to
be a promising biomarker; however, they reported that
more studies are needed to precisely define the effect of
somatic mutations in the PIK3CA gene in the treatment of
colorectal cancer patients [56].
Yan et al. [57] investigated the potential value and
mechanism of PIK3CA mutation in colorectal cancer
chemotherapy. First line chemotherapy response and
PIK3CA mutation correlation were evaluated and
evaluated in 440 colorectal cancer patients in medical
records. The frequency of PIK3CA gene mutation in
colorectal cancer patients has been found to be 9.55%,
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and this has been reported to be associated with late TNM
staging and low histological grade. Colorectal cancer
patients with the PIK3CA mutation have been reported
to respond poorly to primary chemotherapy than those
without the PIK3CA mutation. PIK3CA mutation tumor
cells showed poor sensitivity to first-line chemotherapy
in vitro and in vivo. The findings showed that PI3K/Akt
activation induced by the PIK3CA mutation contributes
to the survival and proliferation of colorectal cancer stem
cells, in which cells are more resistant to chemotherapy.
In colorectal cancer studies, conflicting results have
been reported about the use of PIK3CA, which may be a
predictive marker for treatment. Recent metaanalyses have
shown that mutations in PIK3CA exon 20 may be a marker
for resistance to anti-EGFR treatment [58,59].
When the outcomes of the studies are evaluated,
mutation analyses come to the fore rather than PIK3CA
mRNA expression analysis. However, the relationship
between PIK3CA mutations and the prognosis of colorectal
cancer patients remains unclear.
In our study, PIK3CA mRNA levels decreased in
colorectal tumor tissues compared to control, while
in peripheral blood samples increased compared to
the control group. However, these changes were not
statistically significant. When the outcomes of the studies
are evaluated, in PIK3CA; mutational analysis is more
prominent than mRNA analysis. However, the relationship
between PIK3CA mutations and the prognosis of colorectal
cancer patients remains controversial. In early diagnosis of
patients with colorectal cancer, mRNA analyses associated
with mutation analyses are needed to precisely identify the
PIK3CA effect.
4.7. Relationship between colorectal cancer and EIF2S3
gene expression
EIF2 complex is required for protein synthesis [20]. In our
study, EIF2S3 mRNA levels increased in both colorectal
tumor tissues and peripheral blood samples compared
to the control group. This increase is only important for
the change in the level of EIF2S3 mRNA expressed in the
peripheral blood of the cases. This increase is especially
important in stages I and III peripheral blood samples.
There are not many studies in the literature for EIF2S3
mRNA analysis. According to the data obtained in our
study, the increase in EIF2S3 mRNA level in peripheral
blood samples stands out in colorectal cancer cases and
our data contributes to these limited studies. Further study
is therefore required to understand EIF2S3 mRNA changes
in peripheral blood samples of colorectal cancer patients.
4.8. Relationship between colorectal cancer and EIF4A1
gene expression
To the best of our knowledge, there are no more studies
in the literature regarding EIF4A1 mRNA gene expression
changes. In our study, EIF4A1 mRNA level in colorectal

tumor tissues decreased compared to the control group,
while it increased in peripheral blood compared to the
control group. This increase is important both in the
expression in general peripheral blood and especially
in peripheral blood stages I and III. The malignant
phenotype is the result of largely irregular gene expression.
Transformed cells are due to not only a global increase in
protein synthesis, but also a situation where pro-oncogenic
mRNAs increase translationally. Such mRNAs have been
shown to have longer and more structured 5p-UTRs
that require high levels of eukaryotic initiation factor
4A (EIF4A1) helicase activity for effective transcription.
Therefore, EIF4A1 has begun to attract attention for
cancer therapy. In order to be used as a biomarker in
early diagnosis, detailed studies should be developed on
the mechanisms that make specific mRNAs dependent on
EIF4A1 activity [60]. According to the results presented
in this study, the increase in EIF4A1 mRNA level in
peripheral blood samples stands out in colorectal cancer
cases and our results further contributes to these limited
studies. Further study is therefore required to understand
EIF4A1 mRNA changes in peripheral blood samples of
colorectal cancer patients.
5. Conclusion
The results reported in this study appears to suggest that the
increase in TRIP13 and CPEB4 mRNA levels in peripheral
blood samples of colorectal cancer cases may be a potential
biomarker in early stage diagnosis of colorectal cancer.
Considering the results related to EIF2S3 and EIF4A1
mRNA changes in the patients with colorectal cancer,
the increase in mRNA levels in peripheral blood samples
is remarkable. The major differences in mRNA levels in
peripheral blood samples and tumor tissue samples likely
reflect the tissue-specific specific regulatory mechanisms
for related gene. Increases in the level of mRNA observed
in the early stage of colorectal cancer suggest that relevant
genes may play a role in carcinogenesis. Our data contains
genetic information that may contribute to existing
procedures in terms of diagnosis and prognosis in patients
with colorectal cancer.
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